Effect of Zoledronic Acid on Skeletal Muscle After Bariatric Surgery: A Secondary Analysis From a Randomized Controlled Trial
Authors' conclusion
A single infusion of 5 mg zoledronic acid did not prevent the loss of muscle mass or strength or improve physical function.
Study context
- Population
- Patients referred for bariatric surgery; age 48.9 ± 6.3 years, BMI 42.3 ± 5.3 kg/m²
- Participants
- 59 patients
- Comparison
- Single-dose zoledronic acid 5 mg before bariatric surgery vs placebo
- INTn = 31
- CONn = 28reference
- Primary endpoint
- Body composition (DXA), knee extensor and flexor muscle strength, and physical function
- Follow-up
- 12 months postoperatively
Methodological detailsdouble-blind, placebo-controlled, randomized 1:1
- Double-blind
- Placebo-controlled
- Randomized 1:1
Primary result
As reported in the abstract
Body composition (body weight, fat mass, lean body mass) · 12 months
Loss of lean body mass in both groups
≈14%
Further findings
Absolute and relative muscle strength (knee extensor (KE), knee flexor (KF)) · 12 months
- Absolute strength decline
- 11%-18%
- Relative strength improvement
- 10%-22%
- No between-group differences for absolute or relative muscle strength
Physical function · 12 months
- Improvement in all physical function measures
- 5%-18%
- No between-group differences in physical function measures
Original publication
Effect of Zoledronic Acid on Skeletal Muscle After Bariatric Surgery: A Secondary Analysis From a Randomized Controlled Trial. Obesity (Silver Spring). Published 2 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →